In the Claims:

Please cancel Claims 22-38, and 40-51 without prejudice or disclaimer.

The following Claims 15, 17, 18, and 19 are amended, as indicated in the marked up version included with this response as Attachment A.

15. (2X Amended) A medicament for treating an autoimmune disease, comprising a treatment enhancing amount of a first active ingredient when in combination with a second active ingredient, wherein the first active ingredient is selected from the group consisting of bisphosphonic acids corresponding to general formula (I)



(I),

in which

A_1, A_2, A_3 and A_4 are independently selected from the group consisting of

hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residues, metals of Groups I, II and III of the Periodic Table of the elements, and substituted and unsubstituted ammonium or ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group consisting of alkylene, alkenylene and hydroxyalkylene,

R_1 and R_2 are independently selected from the group consisting of

H, OH, $-NH_2$, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residues, $-SR_3$, C1 and $-NR_3R_4$,

in which

R_3 and R_4 are independently selected from the group consisting of

H, OH, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl and substituted and unsubstituted heterocyclic residues,

their pharmaceutically compatible salts, esters thereof, salts of the esters and compounds, which upon administration from the compounds according to formula (I) or their salts or esters as metabolites or catabolites,

and a treatment enhancing amount of a second active ingredient when in combination with the first active ingredient, wherein said second active ingredient is

at least one autoantigen specific for the autoimmune disease to be treated and selected from the group consisting of nervous system tissue extracts, collagen, thyroglobulin, acetylcholine receptor protein, DNA, islet cell extracts, human insulin, liver extracts, adrenal cortex extracts, skin extracts, muscle extracts, haemopoetic cell line extracts, heart extracts, eye lens proteins, S-antigens, gastric cell extracts, parietal cell extracts, intrinsic factor, and intestinal extracts; and

an excipient.

E1 Cont

17. (2x Amended) A medicament for treating an autoimmune disease, comprising a treatment enhancing amount of a first active ingredient when in combination with a second active ingredient, wherein the first active ingredient is selected from the group consisting of bisphosphonic acids corresponding to general formula (I)



(I),

E2

in which

A_1, A_2, A_3 and A_4 are independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residues, metals of Groups I, II and III of the Periodic Table of the elements, and substituted and unsubstituted ammonium or ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group consisting of $(CH_2)_{1-5}$ and amidino,

R_1 is selected from the group consisting of

H and OH, and

R_2 is selected from the group consisting of



their pharmaceutically compatible salts, esters thereof, salts of the esters and compounds, which upon administration form the compounds according to formula (I) or their salts or esters as metabolites or catabolites,

and a treatment enhancing amount of a second active ingredient when in combination with the first active ingredient, wherein said second active ingredient is

at least one autoantigen specific for the autoimmune disease to be treated and selected from the group consisting of nervous system tissue extracts, collagen, thyroglobulin, acetylcholine receptor protein, DNA, islet cell extracts, human insulin, liver extracts, adrenal cortex extracts, skin extracts, muscle extracts, haemopoetic cell line extracts, heart extracts, eye lens proteins, S-antigens, gastric cell extracts, parietal cell extracts, intrinsic factor, and intestinal extracts; and

an excipient.

18. (2x Amended) The medicament of claim 15, wherein the autoantigen is selected from the group consisting of nervous system tissue extracts, islet cell extracts, liver extracts, adrenal cortex extracts, skin extracts, muscle extracts, haemopoetic cell line extracts, heart extracts, gastric cell extracts, parietal cell extracts, and intestinal extracts.

19. (Amended) The medicament of claim 52, wherein the allergen is pollen.

Claims 52-65 are added as follows and as indicated in the marked up version included with this response as Attachment A.

52. A medicament for treating an allergy, comprising:

a treatment enhancing amount of a first active ingredient when in combination with a second active ingredient, wherein the first active ingredient is selected from the group consisting of

bisphosphonic acids corresponding to general formula (I)



(I),

in which

A_1, A_2, A_3 and A_4 are independently selected from the group consisting of

hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residues, metals of Groups I, II and III of the Periodic Table of the elements, and substituted and unsubstituted ammonium or ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group consisting of alkylene, alkenylene and hydroxyalkylene,

R_1 and R_2 are independently selected from the group consisting of

H, OH, $-NH_2$, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted heterocyclic residues, $-SR_3$, C1 and $-NR_3R_4$,

in which

R_3 and R_4 are independently selected from the group consisting of

H, OH, substituted and unsubstituted acyl, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl and substituted and unsubstituted heterocyclic residues,

their pharmaceutically compatible salts, esters thereof, salts of the esters and compounds, which upon administration from the compounds according to formula (I) or their salts or esters as metabolites or catabolites,

and a treatment enhancing amount of a second active ingredient when in combination with the first active ingredient, wherein said second active ingredient is an allergen ingredient specific for the allergy to be treated and is selected from the group consisting of pollen, nickel, and food; and

an excipient.

53. A medicament for treating an allergy, comprising:

a treatment enhancing amount of a first active ingredient when in combination with a second active ingredient, wherein the first active ingredient is selected from the group consisting of bisphosphonic acids corresponding to general formula (I)



(I),

in which

A_1, A_2, A_3 and A_4 are independently selected from the group consisting of hydrogen, substituted and unsubstituted alkyl, substituted and unsubstituted aryl, substituted and unsubstituted aralkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted heterocyclic residues, metals of Groups I, II and III of the Periodic Table of the elements, and substituted and unsubstituted ammonium or ammonium compounds derived from ethylenediamine or amino acids,

X is absent or is selected from the group consisting of $(CH_2)_{1-5}$ and amidino,

R_1 is selected from the group consisting of

H and OH, and

R_2 is selected from the group consisting of





their pharmaceutically compatible salts, esters thereof, salts of the esters and compounds, which upon administration form the compounds according to formula (I) or their salts or esters as metabolites or catabolites,

and a treatment enhancing amount of a second active ingredient when in combination with the first active ingredient, wherein said second active ingredient is an allergen ingredient specific for the allergy to be treated and selected from the group consisting of pollen, nickel, and food; and

an excipient.

54. The medicament of claim 15, wherein the autoantigen is from a nervous system tissue extract and the autoantigen is myelin basic protein.

55. The medicament of claim 15, wherein the autoantigen is selected from the group consisting of collagen, thyroglobulin, acetylcholine receptor protein, human insulin, eye lens proteins, S-antigens, and intrinsic factor.

56. The medicament of claim 15, wherein the autoantigen is DNA.

57. The medicament of Claim 52, wherein the allergen ingredient is food.

58. The medicament of Claim 15 wherein the bisphosphonic acid is an amino-1-hydroxyalkylidene-1,1-bisphosphonic acid wherein the alkyl is methyl, ethyl, propyl, butyl, or hexyl.

59. The medicament of Claim 15 wherein the bisphosphonic acid is amidinomethylenebisphosphonic acid, ibandronic acid, risedronic acid, zoledronic acid, cimadronic acid, or tiludronic acid.

60. The medicament of Claim 52 wherein the bisphosphonic acid is an amino-1-hydroxyalkylidene-1,1-bisphosphonic acid wherein the alkyl is methyl, ethyl, propyl, butyl, or hexyl.

61. The medicament of Claim 52 wherein the bisphosphonic acid is amidinomethylenebisphosphonic acid, ibandronic acid, risedronic acid, zoledronic acid, cimadronic acid, or tiludronic acid.

62. The medicament of Claim 15 wherein the bisphosphonic acid is an amino-1-hydroxyalkylidene-1,1-bisphosphonic acid wherein the alkyl is methyl, ethyl, propyl, butyl, or hexyl; and the autoantigen is from a nervous system tissue extract and is myelin basic protein.

63. The medicament of Claim 15 wherein the bisphosphonic acid is an amino-1-hydroxyalkylidene-1,1-bisphosphonic acid wherein the alkyl is methyl, ethyl, propyl, butyl, or hexyl; and the autoantigen is collagen.